article thumbnail

STAT+: Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025

STAT

billion in 2025, a spokesperson for the Centers for Medicare and Medicaid Services confirmed to STAT. Medicare’s actuaries expect the drug Leqembi , made by the Japanese drugmaker Eisai and sold in partnership with Biogen, to cost the traditional Medicare program around $550 million in 2024, and the entire Medicare program $3.5

article thumbnail

STAT+: Biden administration sticks with slight cuts to 2025 Medicare Advantage payments

STAT

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities.

Hospitals 363
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top pharma and biotech conferences 2025

PharmaVoice

Mark your calendars for the most important industry conferences in 2025.

253
253
article thumbnail

STAT+: Medicare Advantage market expected to grow in 2025, despite big changes from insurers

STAT

That’s why the federal government expects enrollment in the $500 billion Medicare Advantage program to grow once again in 2025 — a stark contrast from insurers’ cries that modest payment reforms would damage them and seniors’ options.

article thumbnail

No one’s pleased with the government’s pitch for 2025 Medicare Advantage rates

STAT

You’re reading the web version of Health Care Inc.,    STAT’s weekly newsletter  following the flow of money in medicine.    Sign up  to get it in your inbox every Monday. 

Hospitals 339
article thumbnail

STAT+: Lawmakers cast doubt on expert panel studying alcohol for 2025 dietary guidelines

STAT

Alcohol policy researchers are fuming over a letter sent by members of Congress last month, which criticizes a panel of experts charged with assessing the health risks of drinking alcohol.

317
317
article thumbnail

STAT+: Moderna says data show its combination Covid-flu vaccine generates a strong immune response

STAT

The findings, disclosed in a press release, suggest the company may be on track to bring a combination flu and Covid vaccine to the market, potentially as early as autumn 2025.

Immunity 360